CASRAI Dictionary

Tag: nih grant deadlines

  • NIH Grant Deadlines 2026: A Cycle Calendar for Administrators

    NIH grant deadlines follow a fixed three-cycle annual schedule set by activity code, with separate due dates for new, renewal and resubmission applications. For 2026, sponsored-programs offices must additionally track the end of continuous submission (final acceptance August 10, 2026), a new late-application policy taking effect May 25, 2026, and the discontinuation of dedicated AIDS due dates.

    The NIH standard due-date system is the fixed calendar of application deadlines published by the National Institutes of Health that assigns each grant activity code (R01, R21, K series, F series, and others) to one of three annual submission cycles. All applications and associated documents are due by 5:00 PM local time of the applicant organisation on the specified date.

    What Are NIH’s Standard Due Dates for 2026?

    NIH assigns each grant mechanism a fixed due date within each of the three annual cycles, published by grants.nih.gov. New and renewal/resubmission applications for the same activity code fall on different days within the same month, which is the detail most single-applicant guides compress or omit.

    Activity code Application type Cycle I Cycle II Cycle III
    R01, U01 New 5 Feb 5 Jun 5 Oct
    R01, U01 Renewal / resubmission / revision 5 Mar 5 Jul 5 Nov
    K series New 12 Feb 12 Jun 12 Oct
    K series Renewal / resubmission / revision 12 Mar 12 Jul 12 Nov
    R03, R21, R34 New 16 Feb 16 Jun 16 Oct
    R03, R21, R34 Renewal / resubmission / revision 16 Mar 16 Jul 16 Nov
    R15 (AREA) All types 25 Feb 25 Jun 25 Oct
    F series fellowships All types 8 Apr 8 Aug 8 Dec
    R13, U13 (conferences) All types 12 Apr 12 Aug 12 Dec
    P series, R18/U18, R25, T/D series All types 25 Jan 25 May 25 Sep
    SBIR/STTR (R41-R44, U43/U44) All types 5 Sep 5 Jan 5 Apr

    SBIR/STTR mechanisms run on their own offset schedule rather than the calendar-year cycle used for research grants, so administrators tracking a mixed PI portfolio need two calendars side by side, not one.

    How Do NIH’s Three Submission Cycles Work?

    NIH review runs on a fixed sequence after each submission window: scientific merit review, then an advisory council round, then an earliest allowable project start date. Under NIH’s submission policies, Cycle I applications go to merit review in June-July, Cycle II in October-November, and Cycle III in February-March of the following year.

    Cycle Application window Scientific merit review Earliest project start
    Cycle I Jan-Apr June-July September / December
    Cycle II May-Aug October-November April
    Cycle III Sep-Dec February-March July

    Each cycle carries roughly a nine-month lag between application due date and earliest possible award start. For a sponsored-programs office running several PIs across R01, K series and R21 mechanisms, this means the same calendar month can hold a Cycle III new-application deadline for one PI and a Cycle II resubmission deadline for another — the two do not move in lockstep even though both sit on the “NIH calendar.”

    What Are NIH’s Resubmission Rules and the 37-Month Window?

    NIH permits one resubmission (designated A1) of an unfunded application. The resubmission must be submitted for the next appropriate due date and, under long-standing NIH policy, no later than 37 months after the original (A0) application’s submission date. If an A1 is also not funded, the applicant may submit a substantially revised idea as a new A0 application rather than a second resubmission.

    • Only one resubmission (A1) is permitted per original application.
    • The A1 must be submitted within 37 months of the A0 submission date.
    • A1 applications use the renewal/resubmission due dates in the table above, not the “new” dates.
    • After an unsuccessful A1, the next step is a new A0, not a further resubmission.

    For administrators tracking multiple PIs, the 37-month clock is the deadline most likely to be missed silently, because it is not tied to a fixed calendar date and does not appear on any single NIH published list — it has to be calculated per application from each PI’s original A0 submission date.

    What Is Changing for NIH Submitters in 2026?

    Three policy changes affect submissions dated 2026, per grants.nih.gov’s submission policies page (updated 31 March 2026):

    • End of continuous submission. NIH will accept continuous-submission applications (for eligible reviewers, standing study section members and chartered advisory council members) through August 10, 2026 — the close of the continuous-submission receipt period for R01, R21, U01 and related mechanisms.
    • New late-application policy. A revised late-application policy takes effect for due dates on or after 25 May 2026. Late applications will be accepted only in narrow, specific circumstances defined in the funding opportunity announcement, not as a general grace window.
    • Dedicated AIDS due dates discontinued. Beginning with applications considered at the January 2027 Advisory Council round — meaning any application with a due date on or after 25 May 2026 — NIH will no longer maintain separate AIDS and AIDS-related due dates; these applications move to the standard due dates for their activity code.

    All three changes compress the informal flexibility administrators previously used to absorb late PI submissions. A missed internal routing deadline that once could be recovered through continuous submission or a late-policy exception now has materially less room to move from 25 May 2026 onward.

    Building a Multi-PI Master Calendar: FAQs for Sponsored-Programs Staff

    A single-PI due-date list is not sufficient for an office managing a portfolio. The practical fix is a master calendar keyed on activity code + application type + cycle, not on PI name, with each PI’s internal routing deadline set 5-10 business days before the NIH due date to allow for institutional sign-off, biosketch checks and budget justification review. Layer the 37-month resubmission window and the 2026 policy changes above onto that grid, and the office has one reference that survives staff turnover rather than living in an individual administrator’s inbox.

    What is the NIH grant cycle?

    The NIH grant cycle is the recurring three-round annual schedule — Cycle I, II and III — that governs when applications are due, when they undergo scientific merit review, when an advisory council considers them, and the earliest date a project can start, typically nine months after submission.

    When are NIH R01 grants due in 2026?

    New R01 applications are due 5 February, 5 June and 5 October in each cycle. Renewal, resubmission and revision R01 applications use a separate schedule of 5 March, 5 July and 5 November — one month later than new applications in the same cycle.

    How many times can you resubmit an NIH grant application?

    NIH allows one resubmission per original application, designated A1. It must be submitted within 37 months of the original A0 submission date. A second unsuccessful attempt requires starting over as a new A0 application rather than a further resubmission.

    What time are NIH grant applications due?

    NIH applications and all associated documents, including reference letters, are due by 5:00 PM local time of the applicant organisation on the specified due date, regardless of the submitting institution’s time zone or the funding institute’s location.

    None of this replaces reading the specific funding opportunity announcement, which can override standard due dates for a given mechanism or institute. But a shared, cycle-based master calendar — rather than a single-deadline mindset — is what actually scales when an office is tracking ten PIs instead of one, and it is the structural gap the 2026 policy tightening makes newly costly to leave unfilled.

  • NIH Grant Application Cap: What Changed and Why

    The NIH grant application cap is no longer a single rule. Since September 2025, principal investigators (PIs) have faced a firm limit on how many applications they can submit each year. As of June 2026, NIH is now consulting on a second, separate limit — this time on how many grants a PI can hold at once. The two policies are frequently conflated in coverage, but they operate on different mechanisms, timelines, and parts of a research office’s workload.

    Two different NIH caps, explained

    The first cap is already in force. Effective 25 September 2025, NIH limits each principal investigator (PI) or multiple-PI (MPI) team member to a maximum of six new, renewal, resubmission, or revision applications per calendar year. The limit applies per PI, not per institution, and resubmissions count toward the total — so a PI who submits three new applications and then resubmits two after a first review has used five of six slots.

    The cap excludes R13 conference grants and T-series training activity codes. Critically for multi-PI labs, it also excludes collaborative submissions where a researcher is listed only as a co-investigator or other senior/key personnel rather than as PI or MPI. NIH told Inside Higher Ed that only 1.3% of applicants submitted more than six PI/MPI applications in 2024 — the vast majority of investigators were never going to be affected by the ceiling itself.

    The second cap is still a proposal. On 8 June 2026, NIH published NOT-OD-26-086, an RFI seeking comment on a policy that would cap the number of simultaneous Research Project Grants (RPGs) a single PI can hold, with options of two, three, or four concurrent awards. This is a portfolio cap, not a submission cap — it would restrict how many active RPGs a PI can run at once, regardless of how many applications they submitted to get there. Science reported that a three-RPG limit was modelled to free roughly $2 billion and support around 3,020 additional investigators, while a two-RPG cap was modelled to free a larger sum, cited at roughly $3.5 billion. The comment period is open until 3 August 2026.

    Feature Submission cap (in force) Concurrent-award cap (proposed)
    Status Active policy since 25 Sept 2025 RFI (NOT-OD-26-086), comments open to 3 Aug 2026
    What it limits Applications submitted per calendar year RPGs held simultaneously per PI
    Threshold 6 applications (new, renewal, resubmission, revision combined) 2, 3, or 4 concurrent RPGs (options under review)
    Excludes R13 conference grants; T-series training codes; co-I/senior-key-personnel roles Not yet finalised
    Stated rationale Reduce review-system overload, curb AI-assisted mass submission Broaden funding distribution across more investigators

    Why NIH is doing this: the portfolio-management rationale

    Both policies are framed by NIH as portfolio-management measures rather than budget cuts. The submission cap arrived alongside a companion policy on AI-generated content: NIH will not treat applications “substantially developed by AI” as original ideas of the applicant, and post-award detection can trigger a referral to the Office of Research Integrity alongside cost disallowance or termination. NIH told reporters the pairing was meant to stop high-volume, AI-assisted submissions from overwhelming peer review — not to reduce the number of investigators it funds.

    The concurrent-award RFI targets a different bottleneck: funding concentration. NIH’s own modelling, reported by Science, suggests a relatively small number of well-funded PIs hold a disproportionate share of active RPGs, and capping simultaneous awards at two, three, or four would redistribute billions toward early- and mid-career investigators who currently hold zero or one RPG — a structural-limit approach also used in eligibility rules at other national funders.

    • The submission cap manages review-system load.
    • The proposed concurrent-award cap manages funding concentration.
    • Neither policy, as currently described, changes the NIH salary cap (set at $228,000 for 2026), which governs allowable reimbursed salary under an award, not how many awards a PI may hold.

    Answer-first: common questions on the NIH grant application cap

    What is the maximum number of applications for NIH?

    Since 25 September 2025, each principal investigator or multiple-PI team member may submit a maximum of six new, renewal, resubmission, or revision applications per calendar year. Conference (R13) and training (T-series) applications are excluded, as are submissions where the researcher is listed only as a co-investigator rather than PI or MPI.

    What is the new NIH cap for 2026?

    There are two distinct 2026 developments, and they are easily confused with the unrelated NIH salary cap ($228,000 for 2026). The application-submission cap (six per year) took effect in 2025 and remains active. In June 2026, NIH separately opened an RFI, NOT-OD-26-086, proposing to cap how many concurrent RPGs a single PI may hold, with comments due by 3 August 2026.

    Does the application cap include co-investigators and multi-PI teams?

    No. The six-application limit counts applications where a researcher is listed as PI or MPI. Collaborative submissions naming a researcher only as a co-investigator or other senior/key personnel do not count toward that individual’s cap, which is the main structural workaround available to multi-PI labs today.

    When does the NIH RFI comment period close?

    The public comment period for NOT-OD-26-086, the proposal to cap concurrent RPGs per PI, closes on 3 August 2026. Institutions, scientific societies, and individual investigators can submit input directly to NIH before that deadline, ahead of any final policy decision.

    Practical workarounds for multi-PI labs

    Research administrators advising multi-PI groups have several concrete levers under the current (submission-cap) rules:

    • Restructure authorship roles deliberately. Only PI/MPI-listed applications count toward the cap, so labs with more ideas than headroom can route some proposals through a co-investigator or senior/key personnel role for researchers who have used their six slots.
    • Sequence resubmissions carefully. Resubmissions count toward the same total as new submissions, so a PI planning two new R01s and a resubmission must track all three against the ceiling from the start of the cycle, not treat resubmission as “free”.
    • Front-load the strongest applications. With a hard ceiling of six, strategy shifts from “submit broadly” toward prioritising the highest-confidence proposals for limited PI/MPI slots, using non-PI collaborative roles for higher-risk ideas.
    • Track activity codes against the exclusion list. R13 conference grants and T-series training awards fall outside the cap entirely; labs running these should confirm applications aren’t wrongly counted against the six-application limit.
    • Watch the RFI, not just the final rule. With the concurrent-award cap open for comment until 3 August 2026, institutions with PIs holding three or more active RPGs have a narrow window to model exposure before any threshold is finalised.

    Implications for institutions and research offices

    For sponsored-programmes offices, the practical burden shifts from “how many can we submit” to “how do we allocate scarce PI slots.” Portfolio dashboards need to track each PI’s six-application count in real time, since resubmissions and revisions from earlier in the year silently consume capacity. It also raises internal equity questions: early-career PIs who have not yet hit historical submission volumes are effectively unconstrained, while a small number of high-output senior PIs may need support prioritising which six applications matter most.

    If the concurrent-award cap is adopted, the implication is larger still. Research offices would need to model which currently-funded PIs already exceed a prospective two-, three-, or four-RPG ceiling, and plan succession — including early-career co-investigators who could be elevated to PI on a renewal. Both policies also interact with the NIH Grants Policy Statement’s existing budget-deviation rules, under which cost-category deviations of 25% or more from an approved budget may require prior sponsor approval; institutions restructuring PI roles to manage the cap should route resulting scope changes through that existing mechanism.

    What’s next

    The six-application submission cap is settled policy, unlikely to be revisited before NIH gathers a full year of compliance data. The concurrent-award RFI is the item to watch: with comments open until 3 August 2026 and modelled effects ranging from roughly $2 billion (a three-RPG limit) to roughly $3.5 billion (a two-RPG limit) in redistributed funding, the threshold NIH eventually chooses will materially change how research-intensive institutions structure PI status on renewals. Research administration offices tracking funder-mandate changes should treat the comment period as an active planning window, not a wait-and-see notice — the final policy is likely to arrive with limited transition time once published.